Biogen reported better-than-expected first-quarter earnings and revenue on Wednesday, and trimmed its full-year earnings outlook, citing charges related to business development activity.
Investor's Business Daily on MSN
Biogen had a nearly perfect sales sweep, but one beat really stood out
Biogen obliterated Wall Street's first-quarter expectations Wednesday, helped by a nearly perfect sales beat sweep from its growth products.
Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...
Biogen first-quarter profit and revenue rose, buoyed by rising sales from its growth products, led by its drug to treat early ...
Biogen (BIIB) stock is in focus as the company beats forecasts with its Q1 2026 financials and trims its full-year earnings ...
Biogen cut its full-year profit forecast on Wednesday as it booked acquisition-related charges, although its first-quarter ...
Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: ...
Biogen is poised to announce its first-quarter results next week, and analysts predict a marginal drop in the company’s ...
Biogen’s growth was expected to stay flat through the 2030s. A key acquisition and busy late-stage pipeline have relieved the ...
Stoke retains exclusive rights for zorevunersen in the United States, Canada, and Mexico; Biogen receives exclusive rest of world commercialization rights Collaboration broadens Biogen’s rare disease ...
Biogen (NASDAQ:BIIB) is gearing up to announce its quarterly earnings on Thursday, 2025-10-30. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results